Advanced search
Publication Cover
International Journal of Neuroscience Latest Articles
Submit an article Journal homepage
190
Views
0
CrossRef citations to date
0
Altmetric
Case Report

Probable eculizumab-associated hepatotoxicity in a patient with neuromyelitis optica: a case report

Koc Emine Rabiaa Department of Neurology, Faculty of Medicine, Uludag University, Bursa, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-0264-7284View further author information
ORCID Icon,
Turan Ömer Faruka Department of Neurology, Faculty of Medicine, Uludag University, Bursa, TurkeyORCID Iconhttps://orcid.org/0000-0002-6752-1519View further author information
ORCID Icon,
Saridas Furkana Department of Neurology, Faculty of Medicine, Uludag University, Bursa, TurkeyView further author information
,
Elhamida Sarra Lazraka Department of Neurology, Faculty of Medicine, Uludag University, Bursa, TurkeyView further author information
,
Pinar Acar Ozenb Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, TurkeyView further author information
&
Aslı Tuncerb Department of Neurology, Faculty of Medicine, Hacettepe University, Ankara, TurkeyView further author information
Received 12 Dec 2022, Accepted 21 Aug 2023, Published online: 31 Aug 2023

References

  • Wu Y, Zhong L, Geng J. Neuromyelitis optica spectrum disorder: pathogenesis, treatment, and experimental models. Mult Scler Relat Disord. 2019;27:412–418. doi: 10.1016/j.msard.2018.12.002.
  • Jarius S, Paul F, Weinshenker BG, et al. Neuromyelitis optica. Nat Rev Dis Primers. 2020;6(1):85. doi: 10.1038/s41572-020-0214-9.
  • Brod SA. Review of approved NMO therapies based on mechanism of action, efficacy and long-term effects. Mult Scler Relat Disord. 2020;46:102538. doi: 10.1016/j.msard.2020.102538.
  • Wingerchuk DM, Fujihara K, Palace J, et al. Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD. Ann Neurol. 2021;89(6):1088–1098. doi: 10.1002/ana.26049.
  • Hayes W, Tschumi S, Ling SC, et al. Eculizumab hepatotoxicity in pediatric aHUS. Pediatr Nephrol. 2015;30(5):775–781. doi: 10.1007/s00467-014-2990-5.
  • Hillmen P, Hall C, Marsh JCW, et al. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2004;350(6):552–559. doi: 10.1056/NEJMoa031688.
  • Hillmen P, Young NS, Schubert J, et al. The complement ınhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355(12):1233–1243. doi: 10.1056/NEJMoa061648.
  • Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in aquaporin-4–positive neuromyelitis optica spectrum disorder. N Engl J Med. 2019;381(7):614–625. doi: 10.1056/NEJMoa1900866.
  • Howard JF, Barohn RJ, Cutter GR, et al. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis. Muscle Nerve. 2013;48(1):76–84. doi: 10.1002/mus.23839.
  • Kistler AD. Eculizumab in atypical hemolytic–uremic syndrome. N Engl J Med. 2013;369(14):1377–1380.
  • Brodsky A, Mazzocchi O, Sánchez F, et al. Eculizumab in paroxysmal nocturnal hemoglobinuria with Budd-Chiari syndrome progressing despite anticoagulation. Exp Hematol Oncol. 2012;1(1):26. doi: 10.1186/2162-3619-1-26.
  • LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Adverse Drug Reaction Probability Scale (Naranjo) in drug ınduced liver ınjury. Bethesda (MD): National Institute of Diabetes and Digestive And Kidney Diseases; 2012–2019 May 4. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547852/
  • Mastellos D, Papadimitriou JC, Franchini S, et al. A novel role of complement: mice deficient in the fifth component of complement (C5) exhibit ımpaired liver regeneration. J Immunol. 2001;166(4):2479–2486. doi: 10.4049/jimmunol.166.4.2479.
  • Herlitz LC, Bomback AS, Markowitz GS, et al. Pathology after eculizumab in dense deposit disease and C3 GN. J Am Soc Nephrol. 2012;23(7):1229–1237. doi: 10.1681/ASN.2011121186.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.